Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The stool–mucus interface represents the complex physiological boundary in the large intestine where the fecal stream meets the protective mucus layer covering the intestinal epithelium. This interface is characterized by a gradient of oxygen, nutrients, and microbial density, serving as a critical selective barrier that facilitates nutrient absorption while sequestering the dense gut microbiota away from the host's epithelial cells (Johansson et al., 2011, Nature Reviews Gastroenterology & Hepatology). The primary structural component of this interface is the gel-forming mucin MUC2, which forms a dense, inner stratified layer that is normally devoid of bacteria and a loose outer layer where host-microbe interactions occur (Hansson, 2020, Science Immunology). In pathological states such as ulcerative colitis, the integrity of this interface is compromised, leading to direct contact between fecal bacteria and the epithelium, which triggers chronic inflammation. While the stool–mucus interface is not a single molecular target, it is a major focus in pharmacology and biotechnology for the development of mucus-penetrating or mucoadhesive drug delivery systems designed to optimize the local or systemic delivery of therapeutics (Ensign et al., 2012, Advanced Drug Delivery Reviews).
Not applicable as this is a physiological interface/microenvironment rather than a specific molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Stool–mucus interface.